Exile Vol. XXIII no. 1

PROSE The White Butterfly by Dalton Trevisan (translated from the Portugese by Alexis Levitin) 5-6 Natural Selection by Anne Tomfohrde 7-14 Stuck a Feather in His Cap... (for Boo) by Tim Cockey 15-18 An Act of Violence by William McNaughton 19-22 Shall We Now Praise Famous Men? by Lawrence Weber 23-24 POETRY Wake by Dawn Patnode 26 Pebble by Lenore Mayhew 27 Bien: yo respeto... by José Mártí 28 Yes: I respect by José Mártí (translated from the Spanish by Joan Straub) 29 untitled by Mary Schloss 30 Nursing Home by Tim Cockey 31 Maia by Betsy Sloan 32 untitled by Loranna Franz 33 Momento Num Cafe by Manuel Banderia 34 Moment in a Café by Manuel Banderia (translated from the Portoguese by Alexis Levitin) 35 Pleiades by Dawn Patnode 36-37 untitled by Sharon Singleton 39 Travel by Libby Thomas 40 untitled by José Pretlow 41 Melancolía by Rubén Darío 42 Melancholy by Rubén Darío (translated from the Spanish by Joan Straub) 43 Lake Shore Drive by Alison Orleans 44 Repudiation by Tona Dickerson 45 Auvers 1889 by Dawn Patnode 47 Retreat by Deb Allbery 48 An Illusion Of Dancing Figures by Lawrence Weber 50-58 Cloud by Lenore Mayhew 59 ESSAYS Climbing \u27earth\u27s undying monument\u27 by Richard H. Soaper, Jr. 61-71 A Program for the American Land by Lindy Davies 72-77 Kerouac and His Critics (For Amy) by John Kralik 80-82 Cover photograph from a late nineteenth century glass negative found in an Ohio antique shop and used with the permission of its owner

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

Simulating Surveys for ELT-MOSAIC: Status of the MOSAIC Science Case after Phase A

International audienceWe present the consolidated scientific case for multi-object spectroscopy with the MOSAIC concept on the European ELT. The cases span the full range of ELT science and require either 'high multiplex' or 'high definition' observations to best exploit the excellent sensitivity and wide field-of-view of the telescope. Following scientific prioritisation by the Science Team during the recent Phase A study of the MOSAIC concept, we highlight four key surveys designed for the instrument using detailed simulations of its scientific performance. We discuss future ways to optimise the conceptual design of MOSAIC in Phase B, and illustrate its competitiveness and unique capabilities by comparison with other facilities that will be available in the 2020s

Simulating surveys for ELT-MOSAIC: Status of the MOSAIC science case after phase A

We present the consolidated scientific case for multi-object spectroscopy with the MOSAIC concept on the European ELT. The cases span the full range of ELT science and require either ‘high multiplex’ or ‘high definition’ observations to best exploit the excellent sensitivity and wide field-of-view of the telescope. Following scientific prioritisation by the Science Team during the recent Phase A study of the MOSAIC concept, we highlight four key surveys designed for the instrument using detailed simulations of its scientific performance. We discuss future ways to optimise the conceptual design of MOSAIC in Phase B, and illustrate its competitiveness and unique capabilities by comparison with other facilities that will be available in the 2020s